GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Subscribe To Our Newsletter & Stay Updated